SAN DIEGO--(BUSINESS WIRE)--Jan. 6, 2006--Tioga Pharmaceuticals Incorporated announced today a $24 million Series A financing. Tioga Pharmaceuticals is engaged in the development of novel therapies for the treatment of gastrointestinal diseases. Tioga is developing asimadoline, a proprietary small molecule, for treating irritable bowel syndrome (IBS) and post operative ileus.
